TAT-11: Ac-225-labeled Girentuximab for Targeted Alpha Therapy of CAIX-expressing Renal Cell Cancer Xenografts

Ottawa, ON, Canada (UroToday.com) Thirty percent of renal cell carcinoma patients are advanced at diagnosis and face a poor 5 year survival prognosis. In this mouse model study, Ac225-DOTA-Girentuximab was injected at a dose of 50 kBq. Biodistribution was studied at 24, 72, and 168 hours after injection using Zr98 as an imaging agent. Tumor uptake continued up to the maximum 168 hours and absorption in other organs was much less.

Dosing studies using 3.7, 9.3 and 18.5 kBq showed improvement in tumor growth with a mean doubling time of 30 +/- 11 days at maximum dose compared with 17 +/- 5 days for the control group. There was no dose effect on weight or hemotoxicity.

Presented by: Robin Merkx, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Radboudumc, Nijmegen

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada

Login